[Therapeutic efficacy of a course administration of vardenafil--inhibitor of phosphodiesterase-5--in erectile dysfunction].
Iu G Aliaev, А З Винаров, Н Д Ахвледиани
Abstract
Iu G Aliaev, А З Винаров, Н Д Ахвледиани
Abstract
We studied a therapeutic effect of long-term and regular use of vardenafil which is an inhibitor of phosphodiesterase-5 (PDE-5) in patients with erectile dysfunction (n=32, mean age 35.7 +/- 6.8 years). They received the drug daily for 1 month in a dose 10 mg in the evening without direct sexual realization of the drug action. Before the treatment, upon 1 and 2 months of therapy the patients filled in questionnaire International Index of Erectile Function Scale (IIEFS) and underwent pharmacoechodopplerography of the penis. The erection scores by IIEFS after 1 month of vardenafil therapy increased from 17.8 +/- 4.5 to 23.7 +/- 5.3 (p < 0.01). On posttreatment day 30 this parameter went down to 21.9 +/- 5.6 scores (p < 0.01). However, this value was significantly better than the baseline (p < 0.01). The same dynamics was observed in objective indices of penile hemodynamics. Thus, routine daily intake of vardenafil produces a significant and persistent improvement of erectile function.
OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
We studied a therapeutic effect of long-term and regular use of vardenafil which is an inhibitor of phosphodiesterase-5 (PDE-5) in patients with erectile dysfunction (n=32, mean age 35.7 +/- 6.8 years). They received the drug daily for 1 month in a dose 10 mg in the evening without direct sexual realization of the drug action. Before the treatment, upon 1 and 2 months of therapy the patients filled in questionnaire International Index of Erectile Function Scale (IIEFS) and underwent pharmacoechodopplerography of the penis. The erection scores by IIEFS after 1 month of vardenafil therapy increased from 17.8 +/- 4.5 to 23.7 +/- 5.3 (p < 0.01). On posttreatment day 30 this parameter went down to 21.9 +/- 5.6 scores (p < 0.01). However, this value was significantly better than the baseline (p < 0.01). The same dynamics was observed in objective indices of penile hemodynamics. Thus, routine daily intake of vardenafil produces a significant and persistent improvement of erectile function.
Key concepts: Vardenafil, Erectile dysfunction, Medicine, cGMP-specific phosphodiesterase type 5, Sildenafil, Phosphodiesterase inhibitor, Erectile function, Urology